Endocrine Society Urges Congress to Avert Proposed Medicare Physician Payment Cuts

On July 7, the Center for Medicare and Medicaid Services (CMS) released the annual Medicare Physician Fee Schedule (MPFS) proposed rule. This rule outlines the agency’s proposed payment and quality program policies for the upcoming year.

This year’s rule proposes several important policy changes including allowing data collection on important telehealth services provided during the pandemic, revisions to reporting evaluation and management (E/M) services, and new codes proposed for billing the FDA-approved 180-day glucose sensor system. The rule also includes a 4.5% scheduled cut to the conversion factor. The Society is very concerned about this cut and is urging Congress to take action to avert it.

Every year, CMS requests our feedback on their proposed changes, and we respond by submitting a comment letter to the agency. Comments are due on September 7, 2022. We have worked with our Clinical Affairs Core Committee (CACC) and other Endocrine Society members with expertise in telehealth and quality payment issues.

If you are interested in learning more about this rule, you can visit the physician payment page on our website where you can find a one-pager and detailed summary of the rule. In addition, we will host a special Physician Payment Webinar in October to explain the impact of the proposed rule and how you can join our advocacy efforts to avert cuts.

You may also like

  • Endocrine Society Advocacy Updates

    Endocrine Society Endorses Right to IVF Act  In June 2024, the Endocrine Society endorsed the Right to IVF Act, introduced by Senators Cory Booker (D-NJ), Patty Murray (D-WA), and Tammy Duckworth (D-IL) to protect and expand nationwide access to fertility treatment, including in vitro fertilization (IVF). The Right to IVF Act would help individuals and families…

  • August 2024 Endocrine Society Advocacy Update

    Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow…

Find more in